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INTRODUCTION
Primary debulking surgery followed by adjuvant chemothera-
py is considered a standard treatment for ovarian cancer. How-
ever, for patients with advanced ovarian cancer and with a 
high perioperative risk or a low likelihood of achieving optimal 
cytoreduction, neoadjuvant chemotherapy (NAC) followed by 
interval debulking surgery (IDS) may be an alternative treat-
ment option.1-4 After the ICON7 and GOG-218 trials, bevaci-
zumab, a humanized VEGF-neutralizing monoclonal anti-
body, was proposed as an additive to first-line ovarian cancer 
therapies: the ICON7 and GOG-218 trials showed that bevaci-
zumab improved progression-free survival (PFS) when incor-
porated with platinum-based adjuvant chemotherapy.5,6 Ac-
cording to the ANTHALYA trial, bevacizumab-containing NAC 
is safe and increases the complete resection rate after IDS.7 In 
recent years, the number of patients with advanced ovarian 
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cancer treated with this NAC-IDS strategy has increased. 
However, data are scarce on the efficacy and safety of NAC 
regimens that incorporate bevacizumab. In the ANTHALYA 
trial, 15 mg/kg of bevacizumab was added to the NAC regi-
men; however, 7.5 mg/kg of bevacizumab (the dose used in 
ICON7) is the current dose permitted in Korea by the Health 
Insurance Review & Assessment Service.
In this study, we retrospectively investigated the efficacy 
and safety of a bevacizumab-containing NAC regimen fol-
lowed by IDS in patients with newly diagnosed advanced ovar-
ian cancer in Korea. We hypothesized that NAC with bevaci-
zumab could be safely administered to patients with advanced 
ovarian cancer and would lead to more successful IDS, thereby 
improving survival outcomes.
MATERIALS AND METHODS
Study population and patient characteristics
We retrospectively reviewed the medical records of 112 pa-
tients with pathologically confirmed epithelial ovarian cancer 
who received at least one cycle of NAC at Yonsei Cancer Hos-
pital between August 2016 and May 2019. All patients were 
histologically or cytologically confirmed to have International 
Federation of Gynecology and Obstetrics (FIGO) stage IIIC–IV 
epithelial ovarian cancer before starting chemotherapy. Diag-
noses were obtained via either laparoscopic or image-biopsy 
samples or fine-needle aspiration of a tumor site or ascites/
effusion. All surgical procedures were performed by one of five 
gynecologic oncology surgeons at our institute. Histological 
diagnoses were based on World Health Organization criteria, 
and all microscopic slides were reviewed by two experienced 
gynecologic pathologists. 
NAC was performed if at least one of the following three cri-
teria was met:8 1) pulmonary and/or hepatic parenchymal 
metastases were observed in imaging studies before surgery, 
2) the patient was medically inoperable, or 3) optimal cytore-
duction was not achievable owing to a high tumor burden 
(Fagotti score ≥8) observed by diagnostic laparoscopy.9,10 Ac-
cording to our institutional policy, IDS was performed after 
three cycles of NAC. The timing of IDS was delayed when op-
timal cytoreduction was not achievable, as determined at the 
clinician’s discretion.
We excluded patients who had other malignancies (n=1), 
who had been treated with immune checkpoint inhibitors (n=3), 
or who had incomplete medical records owing to loss at follow-
up (n=4). The final study population comprised 104 patients 
(Fig. 1). Patients were divided into two groups based on the 
administration of bevacizumab with NAC. 
The following data were extracted from the patients’ medi-
cal records: age, body mass index (BMI), American Society of 
Anesthesiologists (ASA) score, serum cancer antigen 125 (CA-
125) levels, serum human epididymis protein 4 (HE4) levels, 
FIGO stage, histology, residual disease after IDS, date of pro-
gression or recurrence, and date of last follow up. The present 
study was reviewed and approved by our Institutional Review 
Board (4-2018-0518) in accordance with the Declaration of 
Helsinki and the International Conference on Harmonisation 
Good Clinical Practice guidelines.
NAC, surgery, and perioperative complications 
All NAC regimens included carboplatin and paclitaxel (CP). 
Newly diagnosed 
FIGO stages IIIC–IV 
ovarian, tubal, or 
peritoneal serous 
adenocarcinoma 
who received NAC 
between 2016 and 
2019 (n=112)
Excluded
Other malignancy was accompanied (n=1)
Additionally treated with other agents (n=3)



























Bevacizumab 7.5 mg/kg 
(C5–C18)
IDS
Fig. 1. Flow diagram of the study population consisting of the standard carboplatin-paclitaxel chemotherapy group (CP, n=88) and the bevacizumab-con-
taining chemotherapy group (BCP, n=16). FIGO, Federation of Gynecology and Obstetrics; NAC, neoadjuvant chemotherapy; IDS, interval debulking sur-
gery; AUC, area under the curve.
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In addition, stage IIIC or IV patients for whom optimal prima-
ry cytoreduction was not achievable, owing to a high tumor 
burden, additionally received bevacizumab (BCP). Because 
the study was retrospective, use of the bevacizumab was de-
termined in accordance with the clinician’s discretion, and 16 
patients were treated with BCP. Dosing schedules for NAC 
were as follows: all patients received paclitaxel (175 mg/m2) 
and carboplatin (area under the curve, 5–6 mg/mL/min) ev-
ery 3 weeks for cycles 1–3. Patients in the BCP group addition-
ally received bevacizumab (7.5 mg/kg) every 3 weeks in cycles 
2 and 3. Conventional surgical procedures included the sam-
pling of free fluid or peritoneal washings for cytology; a thor-
ough inspection of the abdomen and pelvis, including the up-
per abdominal viscera, diaphragm, and retroperitoneal 
spaces; and hysterectomy, bilateral oophorectomy and omen-
tectomy, pelvic/para-aortic lymph node dissection, and ap-
pendectomy. Radical surgery included bowel resection, dia-
phragm or other peritoneal surface stripping, splenectomy, 
partial hepatectomy, partial gastrectomy, partial cystectomy 
and/or ureteroneocystostomy, cholecystectomy, and/or dis-
tal pancreatectomy.11-13
Perioperative complications were graded according to the 
Memorial Sloan-Kettering Cancer Center surgical secondary 
events grading system;14,15 a score ≥3 indicated a major compli-
cation. Operative mortality was defined as death occurring 
within 30 days after surgery (grade 5).
Surveillance and follow-up
We routinely evaluated CA-125 levels and performed imaging 
studies for surveillance. Our institutional follow-up strategy 
was to follow up patients every 3 months for the first 2 years 
after treatment and every 6 months thereafter. Recurrence was 
defined as the date of appearance of radiologically detected 
disease during a follow-up examination. An increase in CA-
125 levels without clinical signs of relapse was not considered 
to indicate progression, but prompted further radiological ex-
aminations. PFS was defined as the time from diagnosis to 
objective disease progression on imaging (according to modi-
fied response evaluation criteria in solid tumor (RECSIST), ver-
sion 1.1).
Statistical analysis
The Statistical Package for Social Sciences software (version 
21.0; IBM Corp., Armonk, NY, USA) was used for all statistical 
analyses. Descriptive statistics were used for demographic 
data and are summarized as medians (ranges) or frequencies 
(percentages). Differences in patient characteristics between 
groups were compared with respect to time intervals using chi-
square or Mann-Whitney U tests. Overall survival (OS) and 
PFS were analyzed using the Kaplan-Meier method and log-




Of 112 patients, 104 were eligible for analysis in this study. Of 
these, 88 patients received conventional NAC (CP), and 16 pa-
tients received bevacizumab-containing NAC (BCP). Patient 
and clinical characteristics are shown in Table 1. The median 
ages, mean BMI, and ASA scores of patients in both groups 
were comparable. Although the serum CA-125 and HE4 levels 
and FIGO stages at diagnosis of the BCP group were higher 









Median (range) 58 (39–77) 56 (39–78) 58 (39–78) 0.943
BMI, kg/m2 23.67±3.61 23.38±4.24 23.62±3.69 0.702
FIGO stage 0.164
IIIC 37 (42.0) 3 (18.8) 40 (38.5)
IVA 7 (8.0) 3 (18.8) 10 (9.6)
IVB 44 (50.0) 10 (62.5) 54 (51.9)
Histologic type 0.353
HGSC 80 (81.2) 16 (100) 96 (92.3)
Non-HGSC 8 (9.1) 0 (0.0) 8 (7.7)
Histologic grade 0.353
G1 3 (3.4) 0 (0.0) 3 (2.9)
G2 2 (2.3) 0 (0.0) 2 (1.9)
G3 83 (94.3) 16 (100) 99 (95.2)
Germline BRCA status 0.873
Wild 51 (63.7) 10 (66.7) 61 (64.2)
Mutation 23 (28.7) 3 (20.0) 26 (27.4)
VOUS 6 (7.5) 2 (25.0) 8 (8.4)
Not available* �8� 1� 9�
CA-125 level at 








≤500 U/mL 23 (26.1) 4 (25.0) 27 (26.0) > 0.999
>500 U/mL 65 (73.9) 12 (75.0) 77 (74.0)
HE4 level at  









1 2 (2.3) 0 (0.0) 2 (1.9)
2 47 (53.4) 7 (43.8) 54 (51.9)
3 37 (42.0) 9 (56.3) 46 (44.2)
4 2 (2.3) 0 (0.0) 2 (1.9)
CP, carboplatin+paclitaxel; BCP, bevacizumab+carboplatin+paclitaxel; BMI, 
body mass index; FIGO, International Federation of Gynecology and Obstet-
rics; HGSC, high-grade serous adenocarcinoma; BRCA, breast cancer suscep-
tibility gene; VOUS, variant of unknown significance; CA-125, cancer antigen 
125; HE4, human epididymis protein 4; ASA, American Society of Anes-the-
siologists.
Values are presented as mean±standard deviation or n (%) unless otherwise 
noticed.
*Missing values are excluded from the calculation of percentages, †The HE4 
levels of five patients were not measured at diagnosis.
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than those of the CP group, these differences were not signifi-
cant. Serous carcinoma histology types were found in over 90% 
of all patients. BRCA1 or BRCA2 mutation statuses were com-
parable between both groups.
Feasibility and safety of bevacizumab-containing NAC 
followed by interval debulking surgery
The median number of NAC cycles was three. The frequencies 
of grade ≥3 adverse events during NAC and perioperative 
complications within 30 days after IDS are summarized in Ta-
ble 2. All patients underwent IDS after NAC. Among 104 pa-
tients, 7 (5.8%) experienced major adverse events during NAC. 
Of these, febrile neutropenia and anemia were the most fre-
quent in both groups. One case of gastrointestinal perforation 
occurred in the BCP group, but this result was not significant. 
None of the patients developed grade ≥4 adverse events. 
Regarding perioperative complications after IDS, none of 
the patients developed grade ≥4 adverse events, and the com-
plications are summarized in Table 2. Nineteen (18.3%) pa-
tients experienced perioperative complications within 30 days 
after IDS. Among these complications, blood transfusion was 
the most common in the BCP group (18.8%); however, this was 
not statistically significant. In addition, none of the patients 
developed bleeding complications, thromboembolic compli-
cations, fistulas/abscesses, or perforations in the BCP group.
Response to NAC and surgical treatment 
The responses following NAC are summarized in Table 3. In 
terms of pathological response, omental chemotherapy response 
scores (CRSs) were reported for 97 of 104 patients (93.3%). The 
two groups had comparable omental CRS: a score of 3 was ob-
served in 4 patients (25.0%) in the BCP group and 22 patients 
(27.2%) in the CP group (p=0.736). There were no significant 
differences in the normalization of serum CA-125 and HE4 lev-
els after NAC between the two groups (p=0.899 and p=0.453, 
respectively).
After NAC treatment, all patients underwent IDS. The re-
sults of IDS are shown in Table 4. Regarding types of IDS, most 
patients (n=76, 86.5%) underwent open surgery (86.4% vs. 
87.5% of the CP and BCP groups, respectively, p=1.000). Com-
plete resection rates after IDS (R0 state) were not significantly 
different between the two groups (47.7% vs. 56.3%, respectively, 
p=0.530). 
At the time of analysis, 13 patients (11.2%, excluding 4 pa-
tients lost in follow up) died, and 54 (45.0%) experienced re-









Adverse events grade ≥3 during NAC 0.293
Adverse events 5 (5.7) 2 (12.5) 7 (5.8)
Febrile neutropenia 3 (3.4) 1 (6.3) 4 (3.8)
Anemia 2 (2.3) 0 (0.0) 2 (1.9)
Thrombocytopenia 0 (0.0) 0 (0.0) 0 (0.0)
Fatigue 0 (0.0) 0 (0.0) 0 (0.0)
Gastrointestinal* 0 (0.0) 1 (6.3) 1 (1.0)
Nausea 0 (0.0) 0 (0.0) 0 (0.0)
Infection 0 (0.0) 0 (0.0) 0 (0.0)
Thrombosis 0 (0.0) 0 (0.0) 0 (0.0)
Peripheral neuropathy 0 (0.0) 0 (0.0) 0 (0.0)
Perioperative complication ≥grade 3 up to 30 days after IDS 0.485
Complications 15 (17.0) 4 (25.0) 19 (18.3)
Wound complications† 2 (2.3) 1 (6.3) 3 (2.9)
Infection 6 (6.8) 0 (0.0) 6 (5.8)
Gastrointestinal‡ 4 (4.5) 0 (0.0) 4 (3.8)
Lymphocele 1 (1.1) 0 (0.0) 1 (1.0)
Thromboembolic 2 (2.3) 0 (0.0) 2 (1.9)
Blood transfusion 0 (0.0) 3 (18.8) 3 (2.9)
CP, carboplatin+paclitaxel; BCP, bevacizumab+carboplatin+paclitaxel; NAC, 
neoadjuvant chemotherapy; IDS, interval debulking surgery.
Values are presented as n (%).
*Colonic perforation, †Wound dehiscence, ‡Ileus (3), small bowel obstruc-
tion (1).
Table 3. Responses to NAC Evaluated by Blood Tests, Image Studies, 










1 3 (3.7) 1 (6.3) 4 (4.1)
2 56 (69.1) 11 (68.8) 67 (69.1)
3 22 (27.2) 4 (25.0) 26 (26.8)
Not available* 7� 0� 7�
Response to NAC 0.929
CR 0 (0.0) 0 (0.0) 0 (0.0)
PR 83 (94.3) 15 (93.8) 98 (94.2)
SD 5 (5.7) 1 (6.3) 6 (5.8)
PD 0 (0.0) 0 (0.0) 0 (0.0)
CA-125 after NAC, 








CA-125 normalization after NAC 0.899
Normal 37 (42.0) 7 (43.8) 44 (42.3)
Abnormal 51 (58.0) 9 (56.3) 60 (57.7)
HE4 after NAC†, 
  pmol/L
121.31±125.19 133.15±84.43 124.69±114.29 0.140
HE4 normalization after NAC† 0.453
Normal 14 (40.0) 4 (28.6) 18 (36.7)
Abnormal 21 (60.0) 10 (71.4) 31 (63.6)
NAC, neoadjuvant chemotherapy; CP, carboplatin+paclitaxel; BCP, bevacizum
ab+carboplatin+paclitaxel; CRS, Chemotherapy Response Score; CR, complete 
remission; PR, partial remission; SD, stable disease; PD, progressive disease; 
CA-125, cancer antigen 125; HE4, human epididymis protein 4.
Values are presented as mean±standard deviation or n (%) unless otherwise 
noticed.
*The CRS of 39 patients were not measured after NAC. Missing values are 
excluded from the calculation of percentages, †The HE4 levels of 39 patients 
were not measured after NAC. Missing values are excluded from the calcu-
lation of percentages.
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currence. The relative frequency of patients with recurrence 
was significantly lower in the BCP group than in the CP group 
(18.8% vs. 49.0%, respectively; p=0.023). PFS and OS were ana-
lyzed using Kaplan-Meier curves and log-rank tests; the BCP 
group had longer PFS than the CP group (hazard ratio=0.32, 
95% confidence interval 0.22–0.99; log-rank p=0.048) (Fig. 2A). 
However, owing to the small sample size and short follow-up 
period, there was no significant difference in OS between the 
two groups (hazard ratio=0.82, 95% confidence interval 0.12–
5.8; log-rank p=0.854) (Fig. 2B).
DISCUSSION
In this study, we investigated the feasibility, safety, and effec-
tiveness of bevacizumab-containing NAC followed by IDS for 
advanced epithelial ovarian cancer. Our results indicated that 
bevacizumab could be feasibly and safely added to NAC-IDS 
regimens for advanced ovarian cancer. Despite other trials 
that incorporated bevacizumab in NAC, including the AN-
THALYA and GEICO 1250 trials, at a standard dose of 15 mg/
kg, our institution was limited to using a half dose of bevaci-
zumab (7.5 mg/kg), owing to regulations from the Korean na-
tional health system. Although the number of patients treated 
with bevacizumab in this study was small and the follow-up 
period was short, we observed improved PFS in patients who 
received bevacizumab-containing NAC-IDS with safety end-
points comparable to those in patients who received conven-
tional NAC. The current study showed that, at least, bevacizum-
ab-containing NAC-IDS could be safely applied in real practice 
and could show effects similar to those observed in the ICON-
7 and GOG-0218 trials.
After five phase III randomized clinical trials on combina-
tion therapy including bevacizumab and chemotherapy for 
ovarian cancer,5,6,16-18 the United States Food and Drug Admin-
istration (US FDA) has approved bevacizumab for all lines of 
ovarian cancer management. Based on results from the AU-
RELIA, OSEAN, and GOG-213 trials,16-18 the US FDA approved 
bevacizumab-combined chemotherapy for recurrent ovarian 
cancer,16 and after the ICON-7 and GOG-218 trials,5,6 bevaci-
zumab was approved for naïve primary ovarian cancer. Stan-
dard chemotherapy with bevacizumab in patients with newly 
diagnosed ovarian cancer did not result in improvements in 
OS;19 however, improved PFS was reported by both the ICON-7 
and GOG-218 trials.
For patients with advanced ovarian cancer and with a high 
perioperative risk or a low likelihood of achieving optimal cy-
toreduction, NAC-IDS strategies are alternative treatment op-
tions. After the ICON-7 and GOG-218 trials, studies were con-
ducted on the incorporation of bevacizumab in NAC-IDS. A 
subgroup analysis of the MITO-16A-MaNGO OV2A phase IV 
trial showed that adding bevacizumab to NAC did not impede 
Table 4. Surgical Details and Results of IDS Evaluated by Blood Tests 









Open 76 (86.4) 14 (87.5) 90 (86.5)
Laparoscopy 12 (11.5)   2 (12.5) 14 (11.7)
Residual disease 0.530
None (R0) 42 (47.7)   9 (56.3) 51 (49.0)
Any residual 46 (52.3)   7 (43.7) 53 (51.0)
Interval from IDS to POAC, days 0.002
Median (range) 16 (7–37) 21.5 (10–50) 17 (7–50)
IDS, interval debulking surgery; CP, carboplatin+paclitaxel; BCP, bevacizumab
+carboplatin+paclitaxel; POAC, postoperative adjuvant chemotherapy.
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CP (n=88) BCP (n=16)
PFS events, n (%) 48 (55) 3 (19)




2-year 35   50
Fig. 2. Kaplan-Meier curves of progression-free survival (PFS) (A) and 
overall survival (OS) (B) in patients treated with standard carboplatin-pa-
clitaxel chemotherapy (CP, n=88) and bevacizumab-containing chemo-
therapy (BCP, n=16) regimens.
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IDS and resulted in a similar rate of perioperative complica-
tions, compared to conventional NAC-IDS.20 The ANTHALYA 
trial, a French multicenter non-comparative randomized phase 
II study, showed that bevacizumab could be safely added to 
preoperative NAC and lead to higher complete resection rates 
after IDS. More recently, the GEICO 1250 trial, a randomized 
phase II trial on bevacizumab-containing NAC, demonstrated 
that bevacizumab did not improve complete macroscopic re-
sponse rates or PFS, but did improve surgical operability with-
out increased toxicity.21 The current study showed that beva-
cizumab improved PFS, but did not show any improvement in 
OS. Because the follow-up period was short, more data matu-
rity period will be needed. As for safety, the current study had 
one case of colonic perforation during NAC in BCP group. Af-
ter emergency operation for colonic perforation, the patient re-
covered and then received IDS and the rest of the adjuvant che-
motherapy. According to a multicenter, observational study in a 
real-world clinical study to evaluate the effectiveness of beva-
cizumab treatment based on AURELIA (KGOG 3041; REBE-
CA), grade ≥3 gastrointestinal perforation occurred only in 
1.3% of the safety analysis population.22 In addition, although 
REBECA study was for recurrent ovarian cancer, grade ≥3 ad-
verse events were acceptable in light of real-world experience. 
Accordingly, we suggest that bevacizumab can generally be 
safely added to preoperative NAC, although careful use will be 
required due to the potential for serious complications, such 
as bowel perforation. 
The limitations of current study are that it was retrospective 
and dependent on medical records in addition to being based 
in a single institution. Therefore, the sample size was relatively 
small, and the follow-up period was not sufficiently long to 
calculate OS.
In conclusion, bevacizumab-containing NAC might be safe 
and provide longer PFS than chemotherapy alone in patients 
with advanced ovarian cancer. However, further study is neces-
sary to investigate the impact of bevacizumab-containing NAC 
on OS.
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